Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

Summary

To evaluate the efficacy and safety of AIN457 versus placebo in patients with relapsing multiple sclerosis.

Timeline

Start

2013-06

Primary completion

2014-04

Completion

2014-04

Outcome

Outcome not reported

Stopped: “Study terminated early based upon development of another anti-IL17 fully human monoclonal antibody with better potential for treating MS patients”

Drugs

Indications